pharmaphorum
OCTOBER 1, 2021
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document.
The Pharma Data
JUNE 7, 2023
In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA. “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 28, 2021
The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks.
The Pharma Data
AUGUST 3, 2021
Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0
Drug Discovery World
NOVEMBER 9, 2023
Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.
The Pharma Data
OCTOBER 26, 2020
billion related to certain license and collaboration agreements, and certain other items. The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Business Developments. Research and development expenses were $3.4
Drug Discovery World
SEPTEMBER 6, 2022
Fully booked service providers for manufacturing and sample analyses and more immune-oriented use of gene and cell therapies.” – CBO Aino Kalervo, and VP of Business Development? .” – Andrew Scharenberg, Umoja Biopharma CEO. . Víctor Cervera-Carrascón, Tilt Bio. . Workforce .
Expert insights. Personalized for you.
52 
Let's personalize your content